首页> 外文期刊>European urology >Robotic and laparoscopic radical cystectomy for bladder cancer: Long-term oncologic outcomes
【24h】

Robotic and laparoscopic radical cystectomy for bladder cancer: Long-term oncologic outcomes

机译:机器人和腹腔镜根治性膀胱切除术治疗膀胱癌的长期肿瘤学结果

获取原文
获取原文并翻译 | 示例
           

摘要

Background Extended oncologic outcomes after minimally invasive cystectomy have not been previously reported. Objective To report outcomes of robot-assisted radical cystectomy (RARC) and laparoscopic radical cystectomy (LRC) for bladder cancer (BCa) at up to 12-yr follow-up. Design, setting, and participants All 121 patients undergoing RARC or LRC for BCa between December 1999 and September 2008 at a tertiary referral center were retrospectively evaluated from a prospectively maintained database. Intervention RARC or LRC. Outcome measurements and statistical analysis Primary end points were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) calculated using Kaplan-Meier curves. Secondary end points were survival analysis by number of lymph nodes (LNs) and type of procedure. Surgical outcomes, including complications, were analyzed. Results and limitations Most tumors were muscle invasive (≥pT2; n = 81; 67%) urothelial carcinomas (n = 102; 84%). Extended LN dissection was performed in 98 patients (81%), with a median of 14 nodes removed (interquartile range [IQR]: 8-18). Twenty-four patients (20%) had node-positive disease (N1: 10 [8%]; N2: 14 [12%]). Eight patients (6.6%) had positive soft tissue margins. Median follow-up was 5.5 yr (mean: 5.9; IQR: 4.2-8.2; range: 0.13-12.1). At last follow-up, 58 patients (48%) had no evidence of disease, 3 (2%) were alive with recurrence, 59 (49%) had died, and status was unknown in 1. Twenty-eight patients (23%) died from cancer-specific causes, 20 (17%) from unrelated causes, and 11 (9%) from unknown causes. The 10-yr actuarial OS, CSS, and RFS rates were 35%, 63%, and 54%, respectively. At last follow-up, OS for pT0, pTis/a, pT1, pT2, and pT3 versus pT4 was 67%, 73%, 53%, 50%, and 16% versus 0%, respectively (p = 0.02). At last follow-up, CSS for pT0, pTis/a, pT1, pT2, and pT3 versus pT4 was 100%, 91%, 74%, 77%, and 56% versus 0%, respectively (p = 0.03). Conclusions The longest oncologic outcomes following RARC and LRC for BCa reported demonstrates results similar to those reported for open RC. Continued analysis and direct randomized comparison between techniques is necessary.
机译:背景技术微创膀胱切除术后的肿瘤学结局延长尚未见报道。目的报道长达12年的机器人辅助根治性膀胱切除术(RARC)和腹腔镜根治性膀胱切除术(LRC)治疗膀胱癌(BCa)的结果。设计,设置和参与者从前瞻性维护的数据库中回顾性评估了1999年12月至2008年9月在三级转诊中心接受RARC或LRC的BCa治疗的所有121例患者。干预RARC或LRC。结果测量和统计分析主要终点是使用Kaplan-Meier曲线计算的总生存期(OS),癌症特异性生存期(CSS)和无复发生存期(RFS)。次要终点是通过淋巴结数目(LNs)和手术类型进行生存分析。分析了包括并发症在内的手术结局。结果与局限性大多数肿瘤是肌肉浸润性(≥pT2; n = 81; 67%)尿路上皮癌(n = 102; 84%)。在98例患者(81%)中进行了广泛的LN解剖,中位切除了14个结节(四分位间距[IQR]:8-18)。二十四名患者(20%)患有淋巴结阳性疾病(N1:10 [8%]; N2:14 [12%])。 8名患者(6.6%)的软组织切缘阳性。中位随访时间为5.5年(平均值:5.9; IQR:4.2-8.2;范围:0.13-12.1)。在最后一次随访中,58例患者(48%)没有疾病证据,3例(2%)活着复发,59例(49%)死亡,1例状态未知。28例患者(23%) )死于癌症特定原因,死于不相关原因的有20名(17%),死于未知原因的11名(9%)。 10年的精算OS,CSS和RFS比率分别为35%,63%和54%。在最后一次随访中,pT0,pTis / a,pT1,pT2和pT3与pT4的OS分别为67%,73%,53%,50%和16%对0%(p = 0.02)。在最后一次随访中,pT0,pTis / a,pT1,pT2和pT3与pT4的CSS分别为100%,91%,74%,77%和56%对0%(p = 0.03)。结论对于RCA和LRC,BCa报道的最长的肿瘤学结果表明,结果与开放性RC相似。技术之间的持续分析和直接随机比较是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号